Europe lost $50.00 M of Perrigo's sales while the US grew
Europe is where Perrigo's sales are leaking. Revenue there fell $50.00 M from a year earlier to $371.70 M, more than the company's total decline of $33.50 M, because US sales moved the other way. Part of the hole is self-inflicted: Perrigo sold its Dermacosmetics business, whose brands include ACO, Biodermal and Iwostin, on April 30, 2026, and management says that sale cut net sales by $23.6 million. The rest points to weaker demand, with management citing lower consumption across both the U.S. and Europe.
Why did the US grow while Europe shrank? US sales rose to $626.40 M from $610.90 M, a 2.5% gain after a 9.0% decline the quarter before. Europe's share of sales fell to 36% from 40%. Currency helped rather than hurt: favorable translation added $3.7 million to total net sales. Europe also felt a weaker cough and cold season, which left retailers holding less inventory. So Europe's slide is part portfolio choice and part soft demand, and the filing does not split the remainder between the two.
For investors, Perrigo is becoming more of an American company: the US brought in 61% of sales this quarter, up from 58% a year earlier. Its geography follows where the selling entity sits, not where the customer lives. A smaller Europe means less currency exposure but more dependence on US retailers, where management saw lower retailer inventory levels. Watch whether European consumption recovers once the divestiture laps. If Europe keeps shrinking after that, is Perrigo's international business still worth what the balance sheet says?

